Biofield plans premarket approval application (PMA) later this year:
This article was originally published in Clinica
Executive Summary
Biofield says it plans to submit a PMA for its breast cancer diagnostic system with the US FDA later this year. Enrollment of a double-blinded study was completed earlier this year. In preparation for the device's European launch in 1997, Biofield has set up a marketing division headed by Lee Cohen who will have responsibility for both European and US marketing. Biofield, which raised $19 million in its IPO in March, has developed a non-invasive system which measures cellular electrical charge distributions associated with epithelial cancers (see Clinica No 714, p 13).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.